CFT-7455 is under clinical development by C4 Therapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CFT-7455’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CFT-7455 is under development for the treatment of relapsed or refractory multiple myeloma (MM), mantle cell lymphoma (MCL), follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphomas (PTCL) including Anaplastic Large Cell Lymphoma. The drug candidate is a molecular glue degrader. It is administered by the oral route and acts by targeting IKZF1 and IKZF3. It is being developed based on the TORPEDO platform (Target ORiented ProtEin Degrader Optimizer).
C4 Therapeutics overview
C4 Therapeutics is a pharmaceutical company. Its products are used for treating cancers such as multiple hematologic malignancies, non-Hodgkin’s lymphomas, multiple myeloma and neurological diseases and others. The company utilizes C4T TORPEDO 9, an integrated technology platform to advance drug design and target disease-relevant proteins for degradation. It develops a TAG, a chemical genetic system to understand the consequences of target protein degradation. The company partners with Biogen Inc, Calico LLC and Roche Holding AG to discover, develop and commercialize therapies for anti-aging, neurological diseases and cancer treatments. C4 Therapeutics is headquartered in Watertown, Massachusetts, the US.
For a complete picture of CFT-7455’s drug-specific PTSR and LoA scores, buy the report here.